Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer. Shagisultanova E, Gradishar W, Brown-Glabberman U, Chalasani P, et al. Clin Cancer Res 2023 Jun 26:CCR-23-0117. doi: 10.1158/1078-0432.CCR-23-0117.

Read + Share

Amedeo Smart

Independent Medical Education

Shagisultanova E, Gradishar W, Brown-Glabberman U, Chalasani P, et al. Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer. Clin Cancer Res 2023 Jun 26:CCR-23-0117. doi: 10.1158/1078-0432.CCR-23-0117.
PMID: 37363965